Use of bremelanotide in patients with controlled hypertension

1. A method for treating female sexual dysfunction in a female patient diagnosed with female sexual dysfunction, said method comprising administering more than a single subcutaneous injection of a composition comprising bremelanotide or a pharmaceutically acceptable salt of bremelanotide to the female patient when the patient is anticipating sexual activity, wherein the female patient has controlled hypertension, wherein the composition comprises 1.25 mg to 1.75 mg net peptide weight of bremelanotide, and wherein there is at least 24 hours between each injection and no more than eight injections are administered in a month, thereby treating female sexual dysfunction.

2. A method for treating female sexual dysfunction in a female patient diagnosed with female sexual dysfunction, said method comprising administering more than a single subcutaneous injection of a composition comprising bremelanotide or a pharmaceutically acceptable salt of bremelanotide to the female patient when the patient is anticipating sexual activity, the composition comprising 1.25 mg to 1.75 mg net peptide weight of bremelanotide sufficient to result in a peak plasma concentration of bremelanotide of no more than 120 ng/mL within 60 minutes after administration of the composition, wherein the female patient also has controlled hypertension, and wherein there is at least 24 hours between each injection and no more than eight injections are administered in a month, thereby treating female sexual dysfunction.

3. A method for treating female sexual dysfunction in a female patient diagnosed with female sexual dysfunction, said method comprising administering more than a single subcutaneous injection of a composition comprising bremelanotide or a pharmaceutically acceptable salt of bremelanotide to the female patient when the patient is anticipating sexual activity, the composition comprising an amount of bremelanotide sufficient to result in a peak plasma concentration of bremelanotide of no more than 120 ng/ml within 60 minutes after administration of the composition, wherein the composition comprises 1.50 mg to 1.75 mg net peptide weight of bremelanotide, wherein the female patient also has controlled hypertension, and wherein there is at least 24 hours between each injection and no more than eight injections are administered in a month, thereby treating female sexual dysfunction.

4. The method of claim 3 , wherein the peak plasma concentration of bremelanotide is no more than 100 ng/mL within 60 minutes after administration of the composition.

5. The method of claim 3 , wherein the composition is an aqueous solution comprising an acetate salt of bremelanotide.

6. The method of claim 5 , wherein the acetate salt of bremelanotide is between 6% and 12% acetic acid (w/w) in an aqueous solution of bremelanotide.

7. The method of claim 6 , wherein the composition has a pH of 5.0, and wherein the composition further comprises one or more agents to adjust pH.

8. The method of claim 7 , wherein the one or more agents to adjust pH are selected from the group consisting of hydrochloric acid and sodium hydroxide.

9. The method of claim 3 , wherein the variability in peak plasma concentration within 60 minutes after subcutaneous administration of the composition is a percent coefficient of variation (% CV) less than 30.

10. The method of claim 3 , wherein the female sexual dysfunction is decreased sexual desire.

11. The method of claim 3 , wherein the female sexual dysfunction is hypoactive sexual desire disorder.

12. The method of claim 3 , wherein the female sexual dysfunction is hypoactive sexual desire disorder with female sexual arousal disorder.

13. The method of claim 3 , wherein the female sexual dysfunction is hypoactive sexual desire disorder without female sexual arousal disorder.

14. The method of claim 3 , wherein the composition is an aqueous solution comprising an acetate salt of bremelanotide and glycerin.

15. The method of claim 14 , wherein the composition comprises 2.5% glycerin (w/v).

16. The method of claim 3 , wherein the patient is concurrently taking no more than two anti-hypertensive drugs.

17. The method of claim 3 , wherein the patient has consistently maintained their systolic blood pressure below 130 mm Hg.

18. The method of claim 3 , wherein the patient has consistently maintained their diastolic blood pressure below 80 mm Hg.

19. The method of claim 3 , wherein the composition is provided in a single-use pre-filled syringe.